GPX1-associated prognostic signature predicts poor survival in patients with acute myeloid leukemia and involves in immunosuppression

Zhang, Jian; Peng, Yu‐Hui; He, Yan; Xiao, Yan; Wang, Qinrong; Zhao, Yan; Tin, Zhang; Wu, Chuncheng; Xie, Yuan; Zhou, Jianjiang; Yu, Wenbin; Lü, Dan; Bai, Hua; Chen, Tenxiang; Guo, Penxiang; Zhang, Qifang

doi:10.1016/j.bbadis.2021.166268

Cited by 13 publications

(5 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings are similar to those of several reports. In acute myeloid leukaemia patients, high Gpx-1 expression was associated with poor prognosis [ 22 ]. Similar results have been obtained in patients with renal cell carcinoma (RCC), where high expression of Gpx-1 is positively associated with distant metastases, lymph node metastases, and tumour stage [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Expression of Glutathione Peroxidase 1 (Gpx-1) as an Independent Prognostic Factor in Colon Adenocarcinoma Patients

et al. 2023

View full text Add to dashboard Cite

Several studies revealed that expression levels of glutathione peroxidase 1 (Gpx-1) can be associated with cancer development, mainly through its role in hydroperoxide scavenging by regulating intracellular reactive oxygen species (ROS) levels. Therefore, our aim was to investigate the expression of Gpx-1 protein in a population of Polish patients with colon adenocarcinoma in the absence of any therapy prior to radical surgery. The study was carried out using colon tissue from patients with adenocarcinoma of the colon confirmed by histopathological examination. Gpx-1 antibody was used to determine the immunohistochemical expression of Gpx-1. The Chi2 test or Chi2Yatesa test were used to analyse the associations between the immunohistochemical expression of Gpx-1 and clinical parameters. The relationship between Gpx-1 expression, and 5-year patient survival was examined using Kaplan–Meier analysis and the log-rank test. Intracellular localisation of Gpx-1 was detected by the use of transmission electron microscopy (TEM). Western blot analysis was used for the evaluation of Gpx-1 protein expression levels in cancer cell lines in vitro. Immunohistochemical study revealed that the high expression of Gpx-1 was associated with the tumour’s histological grade, proliferating cell nuclear antigen (PCNA) immunohistochemical expression, depth of invasion, and angioinvasion (all p < 0.001) (4). The high immunohistochemical expression of Gpx-1 is correlated with poor prognosis of colon adenocarcinoma patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Expression of Glutathione Peroxidase 1 (Gpx-1) as an Independent Prognostic Factor in Colon Adenocarcinoma Patients

et al. 2023

View full text Add to dashboard Cite

show abstract

“…GPx is a selenium-containing antioxidant enzyme that protects cells by reducing hydrogen peroxide and lipid peroxide into water and lipid alcohols. GPx1 expression was reported to be associated with the elevation of immunosuppressive MDSCs and TAM and correlated with worse prognosis in AML patients [60]. The overexpression of GPx2 has been found in the group of immunologically cold-type tumors, inversely correlated with the level of proinflammatory cytokines and associated with poor responsiveness to anti-CTLA-4 therapy [61].…”

Section: Antioxidant Metabolism Associated With Cancer Cell Immune Es...mentioning

confidence: 99%

Immunological Aspects of Cancer Cell Metabolism

Ucche,

Hayakawa

2024

IJMS

View full text Add to dashboard Cite

Cancer cells adeptly manipulate their metabolic processes to evade immune detection, a phenomenon intensifying the complexity of cancer progression and therapy. This review delves into the critical role of cancer cell metabolism in the immune-editing landscape, highlighting how metabolic reprogramming facilitates tumor cells to thrive despite immune surveillance pressures. We explore the dynamic interactions within the tumor microenvironment (TME), where cancer cells not only accelerate their glucose and amino acid metabolism but also induce an immunosuppressive state that hampers effective immune response. Recent findings underscore the metabolic competition between tumor and immune cells, particularly focusing on how this interaction influences the efficacy of emerging immunotherapies. By integrating cutting-edge research on the metabolic pathways of cancer cells, such as the Warburg effect and glutamine addiction, we shed light on potential therapeutic targets. The review proposes that disrupting these metabolic pathways could enhance the response to immunotherapy, offering a dual-pronged strategy to combat tumor growth and immune evasion.

show abstract

“…According to Wang’s research, MDSCs were shown to be increased in the peripheral blood of AML patients, and VISTA knockdown significantly decreased the ability of these cells to inhibit PD-1-expressing CD8 + T cells in AML [ 93 ]. Recently, it was found that the expression of GPX1 in AML was positively correlated with MDSC, monocyte and T-cell depletion scores, and interestingly, it was also associated with immunosuppression checkpoints (TIM3/GAL-9, SIRPα, and VISTA), and these checkpoints participate in the immunosuppressive effects of MDSCs [ 94 ]. These potential pathways and targets of mechanistic research provide theoretical support for immune drug application.…”

Section: The Function Of Mdscs In Hematologic Malignanciesmentioning

confidence: 99%

Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies

Wang

Zhao

et al. 2023

Biomark Res

View full text Add to dashboard Cite

The immunosuppressive tumor microenvironment (TME) supports the development of tumors and limits tumor immunotherapy, including hematological malignancies. Hematological malignancies remain a major public health issue with high morbidity and mortality worldwide. As an important component of immunosuppressive regulators, the phenotypic characteristics and prognostic value of myeloid-derived suppressor cells (MDSCs) have received much attention. A variety of MDSC-targeting therapeutic approaches have produced encouraging outcomes. However, the use of various MDSC-targeted treatment strategies in hematologic malignancies is still difficult due to the heterogeneity of hematologic malignancies and the complexity of the immune system. In this review, we summarize the biological functions of MDSCs and further provide a summary of the phenotypes and suppressive mechanisms of MDSC populations expanded in various types of hematological malignancy contexts. Moreover, we discussed the clinical correlation between MDSCs and the diagnosis of malignant hematological disease, as well as the drugs targeting MDSCs, and focused on summarizing the therapeutic strategies in combination with other immunotherapies, such as various immune checkpoint inhibitors (ICIs), that are under active investigation. We highlight the new direction of targeting MDSCs to improve the therapeutic efficacy of tumors.

show abstract

GPX1-associated prognostic signature predicts poor survival in patients with acute myeloid leukemia and involves in immunosuppression

Cited by 13 publications

References 55 publications

Immunohistochemical Expression of Glutathione Peroxidase 1 (Gpx-1) as an Independent Prognostic Factor in Colon Adenocarcinoma Patients

Immunohistochemical Expression of Glutathione Peroxidase 1 (Gpx-1) as an Independent Prognostic Factor in Colon Adenocarcinoma Patients

Immunological Aspects of Cancer Cell Metabolism

Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies

Contact Info

Product

Resources

About